Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Jonathan Rosand

Neurocritical Care · Broad Institute

View

Dr. Jinsy Andrews

ALS · NYU Langone

View

Dr. Maisha Robinson

Hospice & Palliative Care · Mayo Clinic Florida

View

Dr. Michael Kentris

Epilepsy · St. Elizabeth Medical Center

View

Dr. Daniel Correa

Epilepsy · AECOM

View

Dr. Aaron Berkowitz

General Neurology · UCSF

View

Dr. Jose Hernan Posas

Sports Neurology · UVA

View

Dr. Michael Okun

Movement Disorders · UF

View

Dr. Joseph Sirven

Epilepsy · Mayo Clinic College of Medicine

View

Dr. Rachel Marie Salas

Sleep Medicine · Johns Hopkins

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Should We Stop Endovascular Treatment of M2 Occlusions?: A Critical Look at Recent Evidence.

    Aug 25, 2025DOI: 10.1161/strokeaha.125.051578Journal ArticleAHA

    Written by: Amol MehtaDaryl GoldmanEytan RazShashvat DesaiEva MistryThanh NguyenSunil ShethAshutosh JadhavJoseph BroderickPooja KhatriJohanna FifiJeffrey L SaverJ Mocco

    Find these authors on Roon

    AJ
    Dr. Ashutosh Jadhav
    Interventional Neurology · Barrow Neurological Institute

    Summary

    Medium vessel occlusions represent a substantial proportion of patients with acute ischemic stroke. Recently presented randomized controlled trials, ESCAPE-MeVO (Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusions), DISTAL (Endovascular Therapy Plus Best Medical Treatment [BMT] Versus BMT Alone for Medium Distal Vessel Occlusion Stroke), and DISCOUNT (Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion), did not demonstrate a clinical benefit of endovascular thrombectomy in distal and medium vessel occlusions, potentially generating uncertainty about optimal treatment strategies for medium vessel occlusions. Specifically, these results may lead clinicians to hesitate in performing endovascular thrombectomy for M2 occlusions, despite prior evidence indicating benefit in this subgroup. In this review, we critically examine current literature, focusing on anatomic and functional definitions of M2 segments, and highlight the significant heterogeneity in their classification. We place a particular emphasis on proximal as well as dominant M2 branches and the existing evidence, including observational studies, meta-analyses, and prior randomized trials. Additionally, we discuss methodological limitations and patient-selection biases of recent neutral trials, which may warrant caution in the broad application of their findings. Lastly, we propose recommendations for future research, emphasizing the need for refined patient-selection criteria to better identify subgroups most likely to benefit from endovascular thrombectomy, improved classification systems for M2 occlusions, and the exploration of adjunctive and alternative therapies.
    AJDr. Ashutosh Jadhav

    Dr. Ashutosh Jadhav

    Neurology · Interventional Neurology
    Barrow Neurological Institute
    ashutosh